Ashland Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended September 30, 2023. Although the request identifies Q4, this filing reports full-year results; the supplied text does not provide a standalone fourth-quarter income statement.
Business context
Ashland is a global specialty additives and materials company serving consumer and industrial markets in more than 100 countries, with approximately 3,800 employees. Its reportable segments are Life Sciences, Personal Care, Specialty Additives, and Intermediates. Sales outside North America represented 69% of FY2023 sales.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Sales | $2.191 billion | $2.391 billion |
| Gross profit / gross margin | $668 million / 30.5% | $830 million / 34.7% |
| Operating income | $172 million | $333 million |
| Income from continuing operations | $168 million | $181 million |
| Net income | $178 million | $927 million |
| Diluted EPS from continuing operations | $3.13 | $3.20 |
| Adjusted EBITDA (non-GAAP) | $459 million | $590 million |
| Continuing-operations operating cash flow | $294 million | $193 million |
| Capital expenditures | $170 million | $113 million |
| Free cash flow / ongoing free cash flow (non-GAAP) | $124 million / $217 million | $80 million / $127 million |
FY2022 net income included a $726 million after-tax gain on the Performance Adhesives sale, recorded in discontinued operations. FY2023 effective tax rate was negative 5%, including favorable discrete tax items; the non-GAAP effective tax rate excluding key items was 21%.
Cash and cash equivalents were $417 million at year-end, down from $646 million. Total debt was $1.330 billion, versus $1.270 billion; debt to capital employed was 30%, compared with 28%. Available liquidity was $1.115 billion, including cash and unused borrowing capacity. The company reported covenant compliance, a 1.9x consolidated net leverage ratio, and an 8.6x interest coverage ratio. No long-term debt maturity was due within three years; $528 million was due in fiscal 2028.
Segment results
| Segment | FY2023 sales | FY2023 operating income | Adjusted EBITDA margin |
|---|---|---|---|
| Life Sciences | $869 million | $172 million | 28.4% |
| Personal Care | $598 million | $52 million | 22.9% |
| Specialty Additives | $600 million | $10 million | 15.7% |
| Intermediates | $185 million | $50 million | 34.1% |
Material changes versus prior year
- Sales fell 8% ($200 million), principally from lower volumes, including customer destocking and weaker first-half demand associated with China’s reopening; favorable price/mix partly offset the decline.
- Adjusted EBITDA decreased $131 million. Management cited lower volume, partly offset by pricing and lower incentive compensation.
- Gross margin declined 4.2 percentage points, reflecting lower volumes and higher operating costs, including manufacturing, shipping, maintenance and shutdown costs.
- Life Sciences sales rose $54 million and operating income rose $17 million, supported by price/mix and pharmaceutical demand. Personal Care sales declined $80 million, Specialty Additives $119 million, and Intermediates $71 million, primarily reflecting lower volumes.
- FY2023 net income was substantially below FY2022 largely because FY2022 included the Performance Adhesives disposal gain. Continuing-operations income was $13 million lower.
Outlook, management commentary and risks
- Ashland did not issue FY2024 full-year guidance, citing uncertain demand and the timing of recovery. Management expected recovery to be more likely in the second half of FY2024.
- For FY2024 first quarter, Ashland forecast sales of $470–$490 million and adjusted EBITDA of $55–$65 million. October demand showed some sequential improvement, but destocking continued, December visibility was limited, and inventory-control actions were expected to weigh on results.
- Announced portfolio actions include beginning a sale process for the nutraceuticals business; optimizing and consolidating CMC/MC industrial operations and HEC manufacturing; and investing more in higher-value growth businesses. Ashland estimated these actions could reduce annual sales by $200–$225 million, while targeting approximately 200 basis points of adjusted EBITDA margin improvement and 150–200 basis points of return-on-net-assets improvement. The company plans to offset approximately $100 million of stranded costs and lost gross profit.
- Key risks include economic weakness and continued destocking, raw-material and energy costs, competition and pricing pressure, foreign exchange, geopolitical disruption, supply-chain and plant interruptions, cybersecurity, product liability, regulatory changes, and environmental and asbestos liabilities.
- Environmental remediation reserves were $214 million; the upper end of the reasonably possible future cost range was estimated at approximately $465 million. Gross asbestos reserves disclosed for Ashland and Hercules were $281 million and $191 million, respectively; future costs are uncertain and depend on claims, severity, litigation and insurance recoveries.
- Sales to Ukraine, Russia and Belarus were less than 1% of consolidated sales; sales to Israel were approximately 1%. Ashland reported no manufacturing operations in those locations.
- The company reported effective disclosure controls and internal control over financial reporting; the independent auditor issued unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Whether demand recovery and destocking trends support the first-quarter ranges and the expected second-half FY2024 recovery.
- Execution, timing, costs, sales losses and realized margin/return benefits from the announced portfolio actions, including the planned nutraceuticals divestiture.
- Whether operating cash flow and liquidity remain adequate alongside planned capital spending, dividends and share repurchases; $1 billion remained authorized for repurchases at year-end.
- The assumptions and potential cash impact behind environmental and asbestos reserves, insurance receivables and the disclosed reasonably possible exposure ranges. The balance sheet lists an asbestos litigation reserve of $427 million, while the notes disclose gross reserves totaling $472 million; investors should review the reconciliation and presentation in the complete filing.
- Underlying segment volume, pricing and cost trends, particularly Specialty Additives’ sharp operating-income decline and Intermediates’ lower sales and earnings.